This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Managing your metastatic non-small cell lung cancer patients on KEYTRUDA® (pembrolizumab)

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

In order to optimise treatment outcomes as well as patients’ quality of life, it is important to understand immune-related adverse events (irAEs), including their:

Time to onset

Presentation

Management

Early recognition and prompt appropriate treatment of irAEs:1

Increases the likelihood that these will be resolved

Are essential to improve
patient outcomes

Explore these related resources to learn more about managing your patients on KEYTRUDA

Find out more about KEYTRUDA® (pembrolizumab) in mNSCLC

About mNSCLC

Events

Training & resources

Sign up to MSD emails

  • Get the latest product updates
  • Receive cancer resources
  • Be the first to hear about our events
Sign up →

Reference

  1. Daniels GA et al. Emerg Med J 2019;36:369–377.

Supporting documentation

By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PDO-01686 | Date of Preparation: September 2021